Dopl Technologies Raises $6.3 Million to Bring Robotic Ultrasound to Patients Without Access to Specialists
A Washington state startup just raised fresh capital to solve a genuinely persistent healthcare access problem: patients in rural areas often have to travel hours just to get a routine ultrasound. Dopl Technologies, based in Bothell, Washington, closed a $6.3 million seed round led by SpringTide Ventures, bringing its total funding to more than $8 million, according to GeekWire's reporting on the raise.
Dopl's platform consists of three integrated products designed to work together. Traverse is the remote robotic ultrasound system itself, pairing with off-the-shelf ultrasound probes and commercially available robots. Dopl Connect provides the secure connectivity and data layer linking a remote sonographer to the robot at the patient's location. SonoFlex handles distributed clinical workforce and workflow management, letting hospitals coordinate sonographer availability across multiple sites at once.
How the Technology Actually Works for Patients
The system lets a credentialed sonographer perform a diagnostic ultrasound exam remotely, controlling the robot with haptic feedback while maintaining a video connection for direct conversation with the patient and any onsite healthcare personnel, according to GeekWire's technical description of the platform. Because the system is hardware-agnostic, working with existing robots and ultrasound equipment already available in hospitals, it's designed to deploy within a hospital's current infrastructure rather than requiring an entirely new, expensive standalone system.
Dopl Technologies CEO and co-founder Ryan James, a former Nvidia medical AI engineer, explained the mission directly: "This is a critical step toward providing specialty care, anywhere, through telerobotic and autonomous care delivery, bridging the healthcare divide that affects tens of millions of people in the United States alone," according to MassDevice's reporting on the announcement. James co-founded the company alongside Dr. Steve Seslar, a pediatric cardiologist, and Dr. Wayne Monsky, an interventional radiologist.
A Bridge Product While Pursuing FDA Clearance
Rather than waiting years for regulatory approval before generating any revenue or clinical experience, Dopl launched CareBridge, an interim service connecting hospitals with traveling sonographers to provide in-person diagnostic coverage while the robotic platform pursues its 510(k) FDA clearance pathway, according to Citybiz's reporting on the company's regulatory strategy. Participating hospitals using CareBridge have reduced patient wait times by as much as 90%, giving Dopl real clinical relationships and operational data ahead of its planned 2027 FDA submission, a staged commercialization approach worth understanding alongside our broader coverage of what AI automation means for regulated, safety-critical industries specifically.
Dopl estimates a $40 billion annual reimbursement opportunity for U.S. hospitals as telerobotic imaging scales nationally, addressing what the company describes as an access gap affecting more than 50 million people in the United States alone.
Why This Matters for Business
In my four years in sales at a research and advisory firm, I heard directly from CMOs and CEOs about what they wanted from AI, and healthcare access came up consistently as a genuinely underserved problem where technology could make a real, measurable difference rather than just an incremental efficiency gain. Dopl's approach, launching an interim human-staffed service to generate revenue and clinical trust while pursuing regulatory clearance for the fully robotic platform, is a smart de-risking strategy worth understanding for any healthcare or medical device startup navigating a similarly long approval timeline.
The Fast Version
Dopl Technologies raised $6.3 million to advance its telerobotic ultrasound platform toward FDA clearance, bringing total funding to more than $8 million. The system lets remote sonographers perform diagnostic ultrasounds using robotic arms with haptic feedback, targeting rural and underserved patients who otherwise face long travel times for specialist care. The company's interim CareBridge service has already reduced patient wait times by up to 90% while Dopl pursues regulatory approval, expected around 2027.
